FrancophonIA/ELRC3.0 huggingface dataset:
English: Approximately 98% of meloxicam is bound to plasma proteins.
Slovenian: Porazdelitev Približno 98% meloksikama se veže na beljakovine v plazmi.
English: In case of overdose symptomatic treatment should be initiated.
Slovenian: Pri prevelikem odmerjanju je treba uvesti simptomatsko zdravljenje.
English: Loxicom 1.5 mg/ml oral suspension for dogs meloxicam
Slovenian: Loxicom 1,5 mg/ml peroralna suspenzija za pse meloksikam
English: Pharmacologically active substance
Slovenian: NAVEDBA ZDRAVILNE UČINKOVINE
English: EU/2/08/090/003 EU/2/08/090/004 EU/2/08/090/005 EU/2/08/090/032 EU/2/08/090/033
Slovenian: EU/2/08/090/005 EU/2/08/090/032 EU/2/08/090/033
English: Avoid use in any dehydrated, hypovolaemic or hypotensive animals as there is a potential risk of renal toxicity.
Slovenian: Pri dehidriranih, hipovolemičnih ali hipotenzivnih živalih se izogibajte dajanju zdravila zaradi možne nevarnosti toksičnih učinkov na ledvice.
English: Meloxicam: 0.5 mg/ml Sodium benzoate: 1.5 mg/ml
Slovenian: Meloksikam: 0,5 mg/ml Natrijev benzoat:
English: Loxicom 2.5 mg chewable tablets for dogs: EU/2/08/090/023 - 1 x 10 tablets EU/2/08/090/024 - 2 x 10 tablets EU/2/08/090/025 - 10 x 10 tablets EU/2/08/090/026 - 50 x 10 tablets
Slovenian: Loxicom 2,5 mg žvečljive tablete za pse EU/2/08/090/023 - 1 x 10 tabletes EU/2/08/090/024 - 2 x 10 tabletes EU/2/08/090/025 - 10 x 10 tabletes EU/2/08/090/026 - 50 x 10 tabletes
English: EU/2/08/090/001 EU/2/08/090/002
Slovenian: EU/2/08/090/002
English: Shelf life after first broaching the glass vial: 28 days.
Slovenian: Rok uporabnosti po prvem odpiranju stične ovojnine: 28 dni.
English: Treatment is to be continued once daily by oral administration (at 24 hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg bodyweight (i.e. 2 ml/10 kg bodyweight).
Slovenian: Zdravljenje nadaljujemo enkrat dnevno (v 24 urnih presledkih) s peroralnim, vzdrževalnim odmerkom po 0,1 mg meloksikama na kilogram telesne mase (to je 2 ml/10 kg telesne mase).
English: BT35 6PU
Slovenian: Co Down, BT35 6PU Združeno Kraljestvo
English: Loxicom 1 mg chewable tablets for dogs: EU/2/08/090/019 - 1 x 10 tabletes EU/2/08/090/020 - 2 x 10 tabletes EU/2/08/090/021 - 10 x 10 tabletes EU/2/08/090/022 - 50 x 10 tabletes
Slovenian: Loxicom 1 mg žvečljive tablete za pse EU/2/08/090/019 - 1 x 10 tabletes EU/2/08/090/020 - 2 x 10 tabletes EU/2/08/090/021 - 10 x 10 tabletes EU/2/08/090/022 - 50 x 10 tabletes
English: The suspension can be given using either of the two measuring syringes provided in the package.
Slovenian: Suspenzijo je treba odmeriti z merilno brizgo, ki je sestavni del pakiranja.
English: Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg body weight.
Slovenian: Zdravljenje nadaljujte enkrat dnevno (v 24 urnih presledkih) s peroralnim, vzdrževalnim odmerkom po 0,1 mg meloksikama na kilogram telesne mase.
English: Loxicom 0.5 mg/ml oral suspension for dogs meloxicam
Slovenian: Loxicom 0,5 mg/ml, peroralna suspenzija za pse meloksikam
English: 5 ml, 15 ml and 30 ml bottle label
Slovenian: 5 ml, 15 ml in 30 ml plastenka
English: 10 and 20 ml bottle
Slovenian: 10 ml in 20 ml steklenička
English: Alleviation of inflammation and pain in acute and chronic musculo-skeletal disorders in cats.
Slovenian: Umirjanje vnetja in lajšanje bolečine pri akutnih in kroničnih mišično-skeletnih obolenjih pri mačkah.
English: 30 ml and 50 ml bottle
Slovenian: 30 ml in 50 ml steklena viala
English: Pre-treatment with other anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment.
Slovenian: Predzdravljenje z drugimi zdravili s protivnetnim delovanjem lahko povzroči dodatne neželene učinke ali jih okrepi, zato teh zdravil za uporabo v veterinarski medicini ne smemo dajati najmanj 24 ur pred začetkom zdravljenja.
English: Overdose (symptoms, emergency procedures, antidotes): In case of overdose symptomatic treatment should be initiated.
Slovenian: 4.10 Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi) (če je potrebno) V primeru vnosa prevelikega odmerka je treba uvesti simptomatsko zdravljenje.
English: In case of overdose, symptomatic treatment should be initiated.
Slovenian: Pri prevelikem odmerjanju uvedemo simptomatsko zdravljenje.
English: In very rare cases (less than 1 animal in 10,000 animals treated, including isolated reports), haemorrhagic diarrhoea, haematemesis, gastrointestinal ulceration and elevated liver enzymes have been reported.
Slovenian: Zelo redko (pri manj kot 1 živali od 10.000 zdravljenih živali, vključno s posameznimi primeri) so poročali o hemoragični driski, hematemezi, razjedah prebavil in zvišani ravni jetrnih encimov.
English: Marketing authorisation holder: Norbrook Laboratories (Ireland) Limited Rossmore Industrial Estate Monaghan
Slovenian: Imetnik dovoljenja za promet z zdravilom: Norbrook Laboratories (Ireland) Limited Rossmore Industrial Estate Monaghan
English: Loxicom 0.5 mg/ml oral suspension for dogs
Slovenian: Loxicom 0,5 mg/ml peroralna suspenzija za pse
English: Initial treatment is a single oral dose of 0.1 mg meloxicam/kg bodyweight on the first day.
Slovenian: Prvi dan zdravljenja je začetni enkratni peroralni odmerek 0,1 mg meloksikama/kg telesne mase.
English: Carton box 15 and 30 ml bottle
Slovenian: Kartonska škatla: 15 ml in 30 ml plastenka
English: 10 and 32 ml bottle
Slovenian: 10 ml in 32 ml plastenka
English: Loxicom 0.5 mg/ml oral suspension for dogs meloxicam2.
Slovenian: Loxicom 0,5 mg/ml peroralna suspenzija za pse meloksikam2.
English: Excipients: Sodium benzoate
Slovenian: Pomožna snov: Natrijev benzoat
English: Do not use after the expiry date stated on the carton and the bottle.
Slovenian: Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na škatli in brizgi.
English: Initial treatment is a single oral dose of 0.2 mg meloxicam/kg body weight on the first day.
Slovenian: Prvi dan zdravljenja je začetni enkratni peroralni odmerek 0,2 mg meloksikama/kg telesne mase.
English: Dogs: Single administration of 0.2 mg meloxicam/kg bodyweight (i.e. 0.4 ml/10 kg).
Slovenian: Enkratno dajanje 0,2 mg meloksikama na kilogram telesne mase (to je 0,4 ml/10 kg).
English: Alleviation of inflammation and pain in acute and chronic musculo-skeletal disorders.
Slovenian: Umirjanje vnetja in lajšanje bolečine pri akutnih in kroničnih mišično-skeletnih obolenjih.
English: Loxicom 0.5 mg/ml oral suspension for cats
Slovenian: Loxicom 0,5 mg/ml peroralna suspenzija za mačke
English: Typical adverse reactions of non-steroidal anti-inflammatory drugs NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported.
Slovenian: Občasno so poročali o značilnih neželenih učinkih nesteroidnih protivnetnih zdravil, kot so izguba teka, bruhanje, driska, kri v blatu (okultna krvavitev), apatija in odpoved ledvic.
English: Do not use in animals suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Slovenian: Ne uporabite pri živalih z obolenji prebavil, kot so zdraženost prebavil in krvavitev, oslabljeno delovanje jeter, srca ali ledvic ter hemoragične motnje.
English: Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.
Slovenian: Umirjanje vnetja in lajšanje bolečine pri akutnih in kroničnih mišično-skeletnih obolenjih pri psih.
English: Pre-treatment with anti-inflammatory substances may result in additional or increased adverse effects and accordingly a treatment-free period with such drugs should be observed for at least 24 hours before commencement of treatment.
Slovenian: Predzdravljenje z zdravili s protivnetnim delovanjem lahko povzroči dodatne neželene učinke ali jih okrepi, zato se teh zdravil ne sme dajati najmanj 24 ur pred začetkom zdravljenja.
English: BN {number}
Slovenian: Lot {številka}
English: In very rare cases (less than 1 animal in 10,000 animals treated, including isolated reports), haemorrhagic diarrhoea, haematemesis and gastrointestinal ulceration have been reported.
Slovenian: Zelo redko (pri manj kot 1 živali od 10.000 zdravljenih živali, vključno s posameznimi primeri) so poročali o hemoragični driski, hematemezi in razjedi prebavil.
English: For use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders.
Slovenian: Za umirjanje vnetja in lajšanje bolečine pri akutnih in kroničnih mišično-skeletnih obolenjih.
English: Do not use in horses suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Slovenian: Ne uporabite pri konjih z obolenji prebavil, kot so zdraženost prebavil in krvavitve, oslabljeno delovanje jeter, srca ali ledvic ter hemoragične motnje.
English: Marketing authorisation holder Norbrook Laboratories (Ireland) Limited Rossmore Industrial Estate Monaghan
Slovenian: Imetnik dovoljenja za promet z zdravilom Norbrook Laboratories (Ireland) Limited Rossmore Industrial Estate Monaghan
English: Cattle and Pigs:
Slovenian: Uporaba v obdobju brejosti in laktacije: Govedo in prašiči:
English: Do not use in cats suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Slovenian: Ne uporabite pri mačkah z obolenji prebavil, kot so zdraženost prebavil in krvavitve, oslabljeno delovanje jeter, srca ali ledvic ter hemoragične motnje.
English: Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported.
Slovenian: Občasno so poročali o značilnih neželenih učinkih NSAID, kot so izguba teka, bruhanje, driska, kri v blatu (okultna krvavitev), apatija in odpoved ledvic.
English: STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENTS
Slovenian: NAVEDBA UČINKOVIN(E) IN DRUGE(IH) SESTAVIN Vsak ml vsebuje
English: People with known hypersensitivity to Non-Steroidal AntiInflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product.
Slovenian: Osebe z znano preobčutljivostjo na nesteroidna protivnetna zdravila (NSAR) naj se izogibajo stiku z zdravilom za uporabo v veterinarski medicini.
English: Equidae
Slovenian: INDIKACIJAE
English: In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Slovenian: V primeru nenamernega samoinjiciranja se takoj posvetujte z zdravnikom in mu pokažite navodilo za uporabo ali ovojnino.
English: hours before commencement of treatment.
Slovenian: DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
English: Target tissues
Slovenian: España Laboratorios Karizoo
English: Carton
Slovenian: Corby
English: Typical adverse drug reactions of non-steroidal anti-inflammatory drugs (NSAIDs) such as loss of appetite, vomiting, diarrhoea, faecal occult blood, apathy and renal failure have occasionally been reported.
Slovenian: Občasno so poročali o značilnih neželenih učinkih nesteroidnih protivnetnih zdravil (NSAR), kot so izguba teka, bruhanje, driska, kri v blatu (okultna krvavitev),letargija in odpoved ledvic.
English: Should irritation occur and persist, seek medical advice.
Slovenian: Če draženje ne preneha, se posvetujte z zdravnikom.
English: Loxicom 1.5 mg/ml oral suspension for dogs.
Slovenian: Loxicom 1,5 mg/ml peroralna suspenzija za pse meloksikam2.
English: Do not use in dogs suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders.
Slovenian: Ne uporabite pri psih z obolenji prebavil, kot so zdraženost prebavil in krvavitev, oslabljeno delovanje jeter, srca ali ledvic ter hemoragične motnje.
English: Shelf-life after first opening the immediate packaging: 28 days
Slovenian: Rok uporabnosti po prvem odpiranju stične ovojnine: 28 dni
English: Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported.
Slovenian: Občasno so poročali o značilnih neželenih učinkih NSAR, kot so izguba teka, bruhanje, driska, kri v blatu (okultna krvavitev), letargija in odpoved ledvic.
English: Pale yellow solution
Slovenian: Bleda rumena raztopina.
English: QUALITATIVE AND QUANTITATIVE COMPOSITION
Slovenian: KAKOVOSTNA IN KOLIČINSKA SESTAVA En ml vsebuje:
English: Pack size
Slovenian: Pretisni omot
English: The syringe has an integrated adapter and has a kg/body weight graduation.
Slovenian: Brizga ima na batu odmerni obroč in merilno skalo z oznakami telesne mase v kilogramih.
English: Blisters
Slovenian: Kopitarji
English: In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the physician.
Slovenian: V primeru nenamernega zaužitja se takoj posvetujte z zdravnikom in mu pokažite navodila za uporabo ali ovojnino.
English: Ref.: EMA/758850/2009 EMEA/H/C/391
Slovenian: : EMA/5534/2010 EMEA/H/C/391
English: This can result in serious loss of vision and even blindness.
Slovenian: To lahko povzroči resno izgubo vida in celo slepoto.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Lumigan to Allergan Pharmaceuticals Ireland on 8 March 2002.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Lumigan, veljavno po vsej Evropski uniji, odobrila podjetju Allergan Pharmaceuticals Ireland dne 8. marca 2002.
English: Other information about Lumigan:
Slovenian: Druge informacije o zdravilu Lumigan:
English: In all of the studies, the main measure of effectiveness was the reduction in eye pressure.
Slovenian: V vseh študijah je bilo glavno merilo učinkovitosti znižanje očesnega tlaka.
English: Some of these patients carried on receiving the medicines for up to two or three years (379 and 183 patients, respectively).
Slovenian: Nekateri od teh bolnikov so zdravila prejemali do dveh (379 bolnikov) ali treh let (183 bolnikov).
English: Lumigan bimatoprost EPAR summary for the public
Slovenian: Lumigan bimatoprost Povzetek EPAR za javnost
English: The Committee for Medicinal Products for Human Use (CHMP) decided that Lumigan's benefits are greater than its risks and recommended that it be given marketing authorisation.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Lumigan večje od z njim povezanih tveganj in je priporočil, da se za zdravilo odobri dovoljenje za promet.
English: This helps to reduce the pressure inside the eye and the risk of damage.
Slovenian: S tem zniža tlak v očesu in zmanjša nevarnost poškodb.
English: It is available in two strengths, 0.1 and 0.3 mg per millilitre.
Slovenian: Na voljo je v dveh jakostih, 0,1 mg in 0,3 mg na mililiter.
English: Therefore, care should be taken by people who wear soft contact lenses.
Slovenian: Zato morajo biti ljudje, ki uporabljajo mehke kontaktne leče, pri uporabi previdni.
English: What is the risk associated with Lumigan?
Slovenian: Kakšna tveganja so povezana z zdravilom Lumigan?
English: What benefit has Lumigan shown during the studies?
Slovenian: Kakšne koristi je zdravilo Lumigan izkazalo med študijami?
English: It is used in adults with long-term open angle glaucoma (a disease where the pressure in the eye rises because fluid cannot drain out of the eye) and in adults with ocular hypertension (when the pressure in the eye is higher than normal).
Slovenian: Uporablja se pri odraslih bolnikih z dolgotrajnim glavkomom odprtega zakotja (boleznijo, pri kateri se tlak v očesu zviša, ker tekočina ne more iztekati iz očesa) in pri odraslih bolnikih z okularno hipertenzijo (kadar je tlak v očesu višji od običajnega).
English: Lumigan should not be used in people who may be hypersensitive (allergic) to bimatoprost or any of the other ingredients.
Slovenian: Zdravila Lumigan ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) bimatoprost ali katero koli drugo sestavino zdravila.
English: Lumigan is used to reduce the pressure inside the eye.
Slovenian: Zdravilo Lumigan se uporablja za zniževanje tlaka v očesu.
English: Eye pressure is measured in ‘millimetres of mercury' (mmHg).
Slovenian: Očesni tlak se meri v milimetrih živega srebra (mmHg).
English: Because Lumigan 0.1 mg/ml contains higher levels of benzalkonium chloride than Lumigan 0.3 mg/ml, Lumigan 0.1 mg/ml must not be used in people who have had a reaction to a product containing benzalkonium chloride in the past, and had to stop using the product containing it as a result.
Slovenian: Ker zdravilo Lumigan 0,1 mg/ml vsebuje višje ravni benzalkonijevega klorida kot zdravilo Lumigan 0,3 mg/ml, zdravila Lumigan 0,1 mg/ml ne smejo uporabljati osebe, ki so imele v preteklosti reakcijo na izdelke z benzalkonijevim kloridom in so tak izdelek posledično morale prenehati uporabljati.
English: The full EPAR for Lumigan is available here.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Lumigan je na voljo tukaj.
English: The active substance in Lumigan, bimatoprost, is a prostaglandin analogue (a man-made copy of a natural substance, prostaglandin).
Slovenian: Zdravilna učinkovina zdravila Lumigan, bimatoprost, je prostaglandinski analog (umetno pripravljena kopija naravne snovi, prostaglandina).
English: The recommended dose of Lumigan is one drop in the affected eye(s) once a day in the evening.
Slovenian: Priporočeni odmerek je ena kapljica zdravila Lumigan v prizadeto oko/prizadeti očesi enkrat dnevno zvečer.
English: Lumigan acts in the same way and increases the flow of fluid out of the eye.
Slovenian: Zdravilo Lumigan deluje enako in poveča iztekanje tekočine iz očesa.
English: For the full list of all side effects reported with Lumigan, see the Package Leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Lumigan, glejte navodilo za uporabo.
English: When the pressure inside the eye is raised, it causes damage to the retina (the light-sensitive membrane at the back of the eye) and to the optic nerve that sends signals from the eye to the brain.
Slovenian: Zvišan tlak znotraj očesa poškoduje mrežnico (membrano na zadnji strani zrkla, ki je občutljiva za svetlobo) in vidni živec, ki pošilja signale iz očesa v možgane.
English: Why has Lumigan been approved?
Slovenian: Zakaj je bilo zdravilo Lumigan odobreno?
English: In a patient with ocular hypertension or glaucoma, the value is generally higher than 21 mmHg.
Slovenian: Pri bolniku z okularno hipertenzijo ali glavkomom je očesni tlak običajno višji od 21 mmHg.
English: It has also been compared with latanoprost (another prostaglandin analogue used in glaucoma) in a six-month study involving 269 patients.
Slovenian: Zdravilo Lumigan so primerjali tudi z latanoprostom (drugim prostaglandinskim analogom, ki se uporablja za zdravljenje glavkoma) v šestmesečni študiji, ki je vključevala 269 bolnikov.
English: Lumigan has been studied in adults with glaucoma or ocular hypertension.
Slovenian: Zdravilo Lumigan so proučevali pri odraslih bolnikih z glavkomom ali okularno hipertenzijo.
English: The most common side effects with Lumigan (seen in more than 1 patient in 10) are conjunctival hyperaemia (increased blood supply to the eye, leading to redness).
Slovenian: Najpogostejši neželeni učinek zdravila Lumigan (opažen pri več kot 1 bolniku od 10) je konjunktivna hiperemija (zvišan dotok krvi v oko, ki povzroči rdečino očesa).
English: However, the lower strength formulation was better tolerated and was less likely to cause hyperaemia (redness of the eye).
Slovenian: Vendar so bolniki šibkejšo obliko zdravila lažje prenašali, verjetnost pojava hiperemije (rdečine očesa) pri njem pa je bila manjša.
English: Lumigan contains benzalkonium chloride, which is known to discolour soft contact lenses.
Slovenian: Zdravilo Lumigan vsebuje benzalkonijev klorid, ki dokazano obarva mehke kontaktne leče.
English: Adding Lumigan 0.3 mg/ml to existing treatment with a beta-blocker was more effective than continuing to use the beta-blocker on its own.
Slovenian: Dodajanje zdravila Lumigan 0,3 mg/ml k obstoječemu zdravljenju z zaviralcem receptorjev beta je bilo učinkovitejše od nadaljnje samostojne rabe zaviralca receptorjev beta.
English: Lumigan can be used alone or with beta-blocker eye drops (other medicines used for these conditions).
Slovenian: Zdravilo Lumigan se lahko uporablja samostojno ali s kapljicami za oko, imenovanimi zaviralci receptorjev beta (drugimi zdravili za ti dve bolezni).
English: In the eye, prostaglandin increases the drainage of the watery fluid (aqueous humour) out of the eyeball.
Slovenian: Prostaglandin v očesu poveča odvajanje vodene tekočine (prekatne vodke) iz zrkla.
English: How has Lumigan been studied?
Slovenian: Kako je bilo zdravilo Lumigan raziskano?
English: What is Lumigan used for?
Slovenian: Za kaj se zdravilo Lumigan uporablja?
English: Lumigan 0.3 mg/ml was also more effective than latanoprost, with patients using Lumigan achieving a reduction in eye pressure of 6.0 to 8.2 mmHg after six months of treatment compared with 4.9 to 7.2 mmHg with latanoprost.
Slovenian: Zdravilo Lumigan 0,3 mg/ml je bilo učinkovitejše tudi od latanoprosta, saj se je očesni tlak pri bolnikih, ki so uporabljali zdravilo Lumigan, po 6 mesecih zdravljenja znižal od 6,0 do 8,2 mmHg, pri bolnikih, ki so uporabljali latanoprost, pa od 4,9 do 7,2 mmHg.
English: Lumigan 0.3 mg/ml used on its own has been compared with timolol (a beta-blocker used to treat glaucoma) in two 12-month studies involving a total of 1,198 patients.
Slovenian: Samostojno uporabo zdravila Lumigan 0,3 mg/ml so primerjali s timololom (zaviralcem receptorjev beta, ki se uporablja za zdravljenje glavkoma) v dveh študijah, v kateri je bilo skupaj vključenih 1 198 bolnikov in sta trajali 12 mesecev.
English: An additional 12-month study compared Lumigan 0.1 mg/ml with Lumigan 0.3 mg/ml, and with an intermediate strength of 0.125 mg/ml, in 561 patients.
Slovenian: V dodatni 12-mesečni študiji, v kateri je sodelovalo 561 bolnikov, so zdravilo Lumigan 0,1 mg/ml primerjali z zdravilom Lumigan 0,3 mg/ml ter z zdravilom s srednjo jakostjo 0,125 mg/ml.
English: Lumigan is a clear eye drop solution that contains the active substance bimatoprost.
Slovenian: Zdravilo Lumigan je bistra raztopina v obliki kapljic za oko, ki vsebuje zdravilno učinkovino bimatoprost.
English: Lumigan 0.3 mg/ml on its own was more effective than timolol at reducing eye pressure.
Slovenian: Zdravilo Lumigan 0,3 mg/ml je bilo kot samostojno zdravilo za zniževanje očesnega tlaka učinkovitejše od timolola.
English: This effect was maintained after two or three years of treatment, with an average reduction in eye pressure of between 7.1 and 8.6 mmHg with Lumigan used once a day, compared with 4.6 to 6.4 mmHg with timolol.
Slovenian: Pri uporabi zdravila Lumigan enkrat dnevno je bilo povprečno znižanje očesnega tlaka od 7,1 do 8,6 mmHg v primerjavi s 4,6 do 6,4 mmHg pri uporabi timolola.
English: In addition, the following side effects are also seen in more than 1 patient in 10 using Lumigan 0.3 mg/ml: growth of eyelashes and ocular pruritus (itchy eye).
Slovenian: Poleg tega sta bila pri več kot 1 bolniku od 10, ki so jemali zdravilo Lumigan 0,3 mg/ml, opažena še naslednja neželena učinka: rast trepalnic in srbenje očesa.
English: How does Lumigan work?
Slovenian: Kako zdravilo Lumigan deluje?
English: How is Lumigan used?
Slovenian: Kako se zdravilo Lumigan uporablja?
English: After three months, eye pressure was lowered by 7.4 mmHg in the group adding Lumigan, compared with 3.6 mmHg in the group adding placebo.
Slovenian: Po treh mesecih se je očesni tlak bolnikov, katerim so dodali zdravilo Lumigan, znižal za 7,4 mmHg, očesni tlak bolnikov, katerim so dodali placebo, pa za 3,6 mmHg.
English: Lumigan 0.1 mg/ml brought about slightly smaller decreases in IOP than Lumigan 0.3 mg/ml.
Slovenian: Zdravilo Lumigan 0,1 mg/ml je sicer znotrajočesni tlak znižalo manj kot zdravilo Lumigan 0,3 mg/ml.